Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD) Tops Q4 EPS by 1c; Authorizes $5B Buyback Plan; Receives 'Refuse to File' Notification from FDA

January 25, 2011 4:08 PM
Gilead Sciences Inc. (NASDAQ: GILD) reported Q4 EPS of $0.95, $0.01 better than the analyst estimate of $0.94. Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Earnings FDA Hot Earnings Stock Buybacks